Newsworthy

This first-ever direct-to-consumer genetic test can provide information on potential risks to individuals who may not have access to genetic screening, but the information may be misleading without feedback from experts.

This is the first treatment that targets patients with AML and the FLT3-ITD mutation. In this clinical trial, patients who received quizartinib lived longer without disease progression than those receiving chemotherapy.

Hundreds of people with metastatic breast cancer and their caregivers from across the country will attend the 2018 Conference on Metastatic Breast Cancer in Philadelphia on April 20–22, 2018, hosted by Living Beyond Breast Cancer.

NeuVax + Herceptin may provide a clinically meaningful benefit to breast cancer patients with low to intermediate HER2-expression.

The Leukemia & Lymphoma Society (LLS) will be hosting its 8th Annual Rocky Mountain Blood Cancer Conference on Saturday, April 7, 2018, at the Hyatt Regency Aurora-Denver Conference Center. LLS Blood Cancer Conferences are free education events for blood cancer patients, survivors, caregivers, family members and healthcare professionals.

In 2017, the FDA approved two new treatments for patients with hepatocellular carcinoma (HCC), Stivarga and Opdivo. Read about these new treatments for liver cancer.

In November 2017, the FDA approved Alecensa for the treatment of all patients with metastatic non–small-cell lung cancer (NSCLC) and ALK mutation.

In October 2017, the FDA accelerated the approval of Calquence for the treatment of adults with mantle-cell lymphoma who have received at least 1 previous therapy.

Read about Verzenio, which was approved by the FDA in 2017, in combination with fulvestrant, for treatment of women with HR-positive, HER2-positive, HER2-negative advanced, or metastatic breast cancer that progressed after endocrine therapy.